Showing 2011-2020 of 5627 results for "".
- Market Scope: Premium IOLs Expected to Drive Market Growth Over the Next 5 Yearshttps://modernod.com/news/market-scope-premium-iols-expected-to-drive-market-growth-over-the-next-5-years/2477796/The revenue contribution of premium IOLs is expected to grow over the next 5 years as the number and different types of IOL designs offered to cataract and refractive patients seeking better visual outcomes increases, according to a Market Scope report. In 2019, premium IOLs accounted a th
- Report: More Than Half of All Age-Related Macular Degeneration Cases Go Undiagnosedhttps://modernod.com/news/report-more-than-half-of-all-age-related-macular-degeneration-cases-go-undiagnosed/2477776/In the nine major pharmaceutical markets, less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years and older, according to analytics company GlobalData. The company’s latest report, ‘
- Artificial Intelligence Algorithm Can Rapidly Detect Severity of Common Blinding Eye Diseasehttps://modernod.com/news/artificial-intelligence-algorithm-can-rapidly-detect-severity-of-common-blinding-eye-disease/2477752/A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), according to a company news release. The study, published in the April/May issue of Tr
- FDA Issues New Policy for Remote Ophthalmic Assessment and Monitoring Devices During COVID-19https://modernod.com/news/fda-issues-new-policy-for-remote-ophthalmic-assessment-and-monitoring-devices-during-covid-19/2477535/The FDA issued immediate guidance to help expand the capability of remote ophthalmic assessment and monitoring devices. These devices include visual acuity charts, visual field devices, general use ophthalmic cameras, and tonometers. This guidance is intended to help facilitate patient c
- NYU Med School Will Graduate Students Early to Help New York Fight Coronavirushttps://modernod.com/news/nyu-med-school-will-graduate-students-early-to-help-new-york-fight-coronavirus/2477471/As COVID-19 continues to slam New York City hospitals, New York University’s Grossman School of Medicine this week took the dramatic step of letting its graduating class depart early to join the response effort, according to a TIME
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Study Advances Development of Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/study-advances-development-of-gene-therapy-for-x-linked-retinitis-pigmentosa/2477321/A new study marks a significant advance in developing a gene therapy for X-linked retinitis pigmentosa, a hereditary disease that leads to severe sight loss in young males. Researchers at Bascom Palmer Eye Institute, the Department of Ophthalmology a
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic